Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Drug-induced tardive dyskinesia

https://doi.org/10.14412/2074-2711-2020-1-81-86

Full Text:

Abstract

Tardive dyskinesia (TD) is a type caused by the use of different medications. The pathogenesis of TD is associated with dopamine receptor blockade, gamma-aminobutyric acid depletion, cholinergic deficiency, oxidative stress, impaired synaptic plasticity, and neurotoxicity. TD most often occurs after taking metoclopramide, antipsychotics, antidepressants, calcium channel blockers, and other drugs.
The review considers an adequate assessment of the potential risk of TD when the patient uses prescribed drugs, as well as the monitoring and correction of risk factors for TD, discontinuation or replacement of drugs that potentially cause TD, as well as its treatment.


About the Authors

T. M. Ostroumova
Department of Nervous System Diseases and Neurosurgery, Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
11, Rossolimo St., Build. 1, Moscow 119021



V. A. Tolmacheva
Department of Nervous System Diseases and Neurosurgery, Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
11, Rossolimo St., Build. 1, Moscow 119021



O. D. Ostroumova
Russian Medical Academy of Continuing Medical Education, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

2/1, Barrikadnaya St., Build. 1, Moscow 125993

16, First Leonov St., Moscow 129226



V. A. Parfenov
Department of Nervous System Diseases and Neurosurgery, Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
11, Rossolimo St., Build. 1, Moscow 119021



References

1. Volz HP, Gleiter CH. Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-355. doi: 10.2165/00002512-199813050-00002

2. Glazer WM, Morgenstern H, Schooler N, et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry. 1990 Oct;157:585-592. doi: 10.1192/bjp.157.4.585

3. Faurbye A, Rasch PJ, Petersen PB, et al. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand. 1964;40(1): 10-27. doi: 10.1111/j.1600-0447.1964.tb05731.x

4. Summary of the American Academy of Neurology (AAN) guideline regarding management of tardive syndromes. https://www.aan.com/Guidelines/Home/GetGuidelineContent/613

5. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol. 2002 Dec;59(12): 1937-43. doi: 10.1001/archneur.59.12.1937

6. Frei K, Truong DD, Fahn S, et al. The nosology of tardive syndromes. J Neurol Sci. 2018 Jun 15;389:10-16. doi: 10.1016/j.jns.2018.02.008. Epub 2018 Feb 6.

7. Medication-induced movement disorders and other adverse effects of medication. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. American Psychiatric Association; 2013.

8. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017 May 23;88(21):2003-2010. doi: 10.1212/WNL.0000000000003960

9. Zaatreh MM. Anticonvulsant-induced dyskinesia. Expert Opin Drug Saf. 2003 Jul;2(4): 385-393. doi:10.1517/14740338.2.4.385

10. Madruga-Garrido M, Mir P. Tics and other stereotyped movements as side effects of pharmacological treatment. Int Rev Neurobiol. 2013; 112:481-494. doi: 10.1016/ B978-0-12-411546-0.00016-0

11. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, doubleblind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017 May; 174(5):476-484. doi: 10.1176/appi.ajp.2017.16091037

12. Diagnostic and statistical manual of mental disorders: DSM-5. Washington: American Psychiatric Association; 2013. 947 p.

13. Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2011;2: CD000209.

14. Mendhekar DN, Gupta N. Combination therapy of levosulpiride and lamotrigine associated with tardive dyskinesia. Aust N Z J Psychiatry. 2009 Feb;43(2):178-179

15. Tisdale JE, Miller DA, editors. Drug-induced diseases: prevention, detection, and management. 3rd edition. Bethesda: American Society of Health-System Pharmacists; 2018. 1399 p.

16. Hergü ner Mö , Incecik F, Altunbasak S. Oxcarbazepine-induced tardive dyskinesia: A rare adverse reaction. J Pediatr Neurosci. 2010 Jan;5(1):85-86. doi: 10.4103/1817-1745.66664.

17. Woerner MG, Kane JM, Lieberman JA, et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol. 1991 Feb;11(1):34-42.

18. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013 Jul 30; 81(5):463-9. doi: 10.1212/WNL.0b013e31829d86b6.

19. Granacher RP Jr. Facial dyskinesia after antihistamines. N Engl J Med. 1977 Mar 3; 296(9):516. doi: 10.1056/ NEJM197703032960917

20. Rodnitzky RL. Drug-induced movement disorders in children and adolescents. Expert Opin Drug Saf. 2005 Jan;4(1):91-102. doi: 10.1517/14740338.4.1.91

21. El-Sayeh HG, Lyra da Silva JP, Rathbone J, et al. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2006;1:CD000458.

22. Essali A, Deirawan H, Soares-Weiser K, et al. Calcium channel blockers for neurolepticinduced tardive dyskinesia. Cochrane Database Syst Rev 2011;11:CD000206.

23. Tenback DE, van Harten PN. Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol. 2011;98:211-30. doi: 10.1016/B978-0-12-381328-2.00009-2

24. Barone DA, Raniolo J. Facial dyskinesia from overdose of an antihistamine. N Engl J Med. 1980 Jul;303(2):107. doi: 10.1056/NEJM198007103030211

25. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008 Mar;21(2):151-6. doi: 10.1097/YCO.0b013e3282f53132

26. Clark BG, Araki M, Brown HW. Hydroxyzine-associated tardive dyskinesia. Ann Neurol. 1982 Apr;11(4):435. doi: 10.1002/ana.410110423

27. Adelufosi AO, Abayomi O, Ojo TM. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2015;4:CD010501.

28. Peluso MJ, Lewis SW, Barnes TR, Jones PB. Extrapyramidal motor side-effects of first-and second-generation antipsychotic drugs. Br J Psychiatry. 2012 May;200(5):387-92. doi: 10.1192/bjp.bp.111.101485

29. Fountoulakis KN, Tegos T, Kimiskidis V. Lithium monotherapy-induced tardive dyskinesia. J Affect Disord. 2019 Feb;244:78-79. doi: 10.1016/j.jad.2018.10.094

30. Klawans HL, Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry. 1974 Aug;37(8):941-947. doi: 10.1136/jnnp.37.8.941

31. Chakrabarti S, Chand PK. Lithium - induced tardive dystonia. Neurol India 2002; 50:473-5

32. Fernandez HH, Friedman JH. Сlassification and treatment of tardive syndromes. Neurologist. 2003 Jan;9(1):16-27. doi: 10.1097/01.nrl.0000038585.58012.97

33. Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry. 2008 Oct; 193(4):279-88. doi: 10.1192/bjp.bp.108.050088

34. Jhang KM, Huang JY, Nfor ON, et al. Extrapyramidal symptoms after exposure to calcium channel blocker-flunarizine or cinnarizine. Eur J Clin Pharmacol. 2017 Jul;73(7): 911-916. doi: 10.1007/s00228-017-2247-x

35. Cornett EM, Novitch M, Kaye AD, et al. Medication-Induced Tardive Dyskinesia: A Review and Update. Ochsner J. 2017;17(2): 162-174.

36. Vaiman EE, Shnayder NA, Neznanov NG, Nasyrova RF. Antipsychotic-induced tardive dyskinesia as a serious adverse effect in the psychopharmacotherapy of schizophrenia. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(4):4-13. (In Russ.). doi: 10.14412/2074-2711-2019-4-4-13

37. Kulkarni SK, Naidu PS. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drugs Today (Barc). 2003 Jan;39(1):19-49. doi: 10.1358/dot.2003.39.1.799430

38. Glazer WM, Morgenstern H, Schooler N, et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry. 1990 Oct;157:585-592. doi: 10.1192/bjp.157.4.585

39. Fedorenko OY, Loonen AJM, Lang F et al. Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia. Int J Neuropsychopharmacol. 2014 Dec 28;18(6): pyu098. doi: 10.1093/ijnp/pyu098

40. Summary of the American Academy of Neurology (AAN) guideline regarding management of tardive syndromes. https://www.aan.com/Guidelines/Home/GetGuidelineContent/613

41. Basile VS, Masellis M, Badri F, et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology. 1999 Jul;21(1):17-27. doi: 10.1016/S0893-133X(98)00114-6.

42. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017 May 23;88(21):2003-2010. doi: 10.1212/WNL.0000000000003960

43. Liao DL, Yeh YC, Chen HM, et al. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology. 2001; 44(2):95-98. doi: 10.1159/000054924

44. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013 Jul 12;3. pii: tre-03-161-4138-1. doi: 10.7916/D88P5Z71. Print 2013.

45. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, doubleblind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017 May; 174(5):476-484. doi: 10.1176/appi.ajp.2017.16091037

46. Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2011;2: CD000209.

47. Katunina EA, Titova NV, Shipilova NN, et al. Current approaches to drug-induced dyskinesias treatment. Journal of Nervnye bolezni. 2017; (2):10-20. (In Russ.).

48. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013 Jul 30; 81(5):463-9. doi: 10.1212/WNL.0b013e31829d86b6.

49. Guy W. ECDEU Assessment Manual for Psychopharmacology: Revised (DHEW publication number ADM 76-338). Rockville, MD, US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. P. 534–7.

50. Kruk J, Sachdev P, Singh S. Neurolepticinduced respiratory dyskinesia. J Neuropsychiatry Clin Neurosci. 1995 Spring;7(2):223-229. doi: 10.1176/jnp.7.2.223

51. El-Sayeh HG, Lyra da Silva JP, Rathbone J, et al. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2006;1:CD000458.

52. Essali A, Deirawan H, Soares-Weiser K, et al. Calcium channel blockers for neurolepticinduced tardive dyskinesia. Cochrane Database Syst Rev 2011;11:CD000206.

53. McCreadie RG, Padmavati R, Thara R, Srinivasan TN. Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up. Br J Psychiatry. 2002 Aug;181:135-137.

54. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry. 2000;61 Suppl 4:10-14.

55. Adelufosi AO, Abayomi O, Ojo TM. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2015;4:CD010501.

56. Schwartz M, Hocherman S. Antipsychoticinduced rabbit syndrome: epidemiology, management and pathophysiology. CNS Drugs. 2004;18(4):213-220. doi: 10.2165/00023210-200418040-00002

57. Klawans HL, Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry. 1974 Aug;37(8):941-947. doi: 10.1136/jnnp.37.8.941

58. Fernandez HH, Friedman JH. Сlassification and treatment of tardive syndromes. Neurologist. 2003 Jan;9(1):16-27. doi: 10.1097/01.nrl.0000038585.58012.97

59. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006 Mar;3(3):138-148. doi: 10.1038/ncpgasthep0442

60. ANI Pharmaceuticals, Inc. Reglan (metoclopramide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017854s058lbl.pdf

61. Abell TL, Bernstein RK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil. 2006 Apr;18(4):263-83. doi: 10.1111/j.1365-2982.2006.00760.x

62. Parkman HP, Hasler WL, Fisher RS. American gastroenterological association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004 Nov;127: 1592-1622. doi: 10.1053/j.gastro.2004.09.055

63. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010 Jan;31(1):11-19. doi: 10.1111/j.1365-2036.2009.04189.x.

64. Al-Saffar A, Lennernä s H, Hellströ m PM. Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited. Neurogastroenterol Motil. 2019 May;2:e13617. doi: 10.1111/nmo.13617

65. Mendhekar DN, Andrade C. Prochlorperazine-induced tardive dystonia and its worsening with clozapine in a non-mentally ill patient with migraine. Ann Pharmacother. 2011 Apr;45(4): 545-546. doi: 10.1345/aph.1-194

66. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? Mov Disord. 2006; 21:589–598. doi: 10.1002/mds.20823

67. Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical and conventional antipsychotic medications: prospective cohort study. J Clin Psychiatry. 2010 Apr;71(4):463-74. doi: 10.4088/JCP.07m03890yel. Epub 2010 Feb 9.

68. Loughlin AM, Lin N, Abler V, Carroll B. Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States. PLoS One. 2019 Jun 4;14(6):e0216044. doi: 10.1371/journal.pone.0216044

69. Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and secondgeneration antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018 Oct; 17(3): 330–340. doi: 10.1002/wps.20579

70. Dubovsky SL, Thomas M. Tardive dyskinesia associated with fluoxetine. Psychiatr Serv. 1996 Sep;47(9):991-993. doi: 10. 1176/ps.47.9.991

71. Roy D. A rare instance of tardive dyskinesia with SSRI use: A case study. European Psychiatry. 2017;41:S759. doi: 10.1016/j.eursy.2017.01.1424

72. Raveendranathan D, Rao SG. Sertraline induced acute mandibular dystonia. J Neurosci Rural Pract. 2015;6(4):586–587. doi:10.4103/0976-3147.169804

73. Volz HP, Gleiter CH. Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-355. doi: 10.2165/00002512-199813050-00002

74. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol. 2002 Dec;59(12): 1937-43. doi: 10.1001/archneur.59.12.1937

75. Zaatreh MM. Anticonvulsant-induced dyskinesia. Expert Opin Drug Saf. 2003 Jul;2(4): 385-393. doi:10.1517/14740338.2.4.385

76. Madruga-Garrido M, Mir P. Tics and other stereotyped movements as side effects of pharmacological treatment. Int Rev Neurobiol. 2013; 112:481-494. doi: 10.1016/ B978-0-12-411546-0.00016-0

77. Mendhekar DN, Gupta N. Combination therapy of levosulpiride and lamotrigine associated with tardive dyskinesia. Aust N Z J Psychiatry. 2009 Feb;43(2):178-179

78. Hergü ner Mö , Incecik F, Altunbasak S. Oxcarbazepine-induced tardive dyskinesia: A rare adverse reaction. J Pediatr Neurosci. 2010 Jan;5(1):85-86. doi: 10.4103/1817-1745.66664.

79. Granacher RP Jr. Facial dyskinesia after antihistamines. N Engl J Med. 1977 Mar 3; 296(9):516. doi: 10.1056/ NEJM197703032960917

80. Barone DA, Raniolo J. Facial dyskinesia from overdose of an antihistamine. N Engl J Med. 1980 Jul;303(2):107. doi: 10.1056/NEJM198007103030211

81. Clark BG, Araki M, Brown HW. Hydroxyzine-associated tardive dyskinesia. Ann Neurol. 1982 Apr;11(4):435. doi: 10.1002/ana.410110423

82. Fountoulakis KN, Tegos T, Kimiskidis V. Lithium monotherapy-induced tardive dyskinesia. J Affect Disord. 2019 Feb;244:78-79. doi: 10.1016/j.jad.2018.10.094

83. Chakrabarti S, Chand PK. Lithium - induced tardive dystonia. Neurol India 2002; 50:473-5

84. Jhang KM, Huang JY, Nfor ON, et al. Extrapyramidal symptoms after exposure to calcium channel blocker-flunarizine or cinnarizine. Eur J Clin Pharmacol. 2017 Jul;73(7): 911-916. doi: 10.1007/s00228-017-2247-x

85. Vaiman EE, Shnayder NA, Neznanov NG, Nasyrova RF. Antipsychotic-induced tardive dyskinesia as a serious adverse effect in the psychopharmacotherapy of schizophrenia. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(4):4-13. (In Russ.). doi: 10.14412/2074-2711-2019-4-4-13

86. Glazer WM, Morgenstern H, Schooler N, et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry. 1990 Oct;157:585-592. doi: 10.1192/bjp.157.4.585

87. Summary of the American Academy of Neurology (AAN) guideline regarding management of tardive syndromes. https://www.aan.com/Guidelines/Home/GetGuidelineContent/613

88. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017 May 23;88(21):2003-2010. doi: 10.1212/WNL.0000000000003960

89. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, doubleblind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017 May; 174(5):476-484. doi: 10.1176/appi.ajp.2017.16091037

90. Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2011;2: CD000209.

91. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013 Jul 30; 81(5):463-9. doi: 10.1212/WNL.0b013e31829d86b6.

92. El-Sayeh HG, Lyra da Silva JP, Rathbone J, et al. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2006;1:CD000458.

93. Essali A, Deirawan H, Soares-Weiser K, et al. Calcium channel blockers for neurolepticinduced tardive dyskinesia. Cochrane Database Syst Rev 2011;11:CD000206.

94. Adelufosi AO, Abayomi O, Ojo TM. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2015;4:CD010501.

95. Klawans HL, Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry. 1974 Aug;37(8):941-947. doi: 10.1136/jnnp.37.8.941

96. Fernandez HH, Friedman JH. Сlassification and treatment of tardive syndromes. Neurologist. 2003 Jan;9(1):16-27. doi: 10.1097/01.nrl.0000038585.58012.97


For citation:


Ostroumova T.M., Tolmacheva V.A., Ostroumova O.D., Parfenov V.A. Drug-induced tardive dyskinesia. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(1):81-86. (In Russ.) https://doi.org/10.14412/2074-2711-2020-1-81-86

Views: 225


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)